XenoPort Inc. is a biopharmaceutical company focused on commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States. HORIZANT has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. RLS, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic (nerve) pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. HORIZANT is also being evaluated under a clinical trial agreement with the National Institute on Alcohol Abuse and Alcoholism, or NIAAA, whereby the NIAAA is conducting a clinical trial of HORIZANT as a potential treatment for patients with alcohol use disorder, or AUD. XenoPort is supplying clinical trial product for, and will have access to data resulting from, this study.
![XenoPort logo](https://files.capedge.com/424B5/0001193125-10-276624/g124587g00t99.jpg)
Company profile
Ticker
XNPT
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943330837
Latest filings (excl ownership)
15-12G
Securities registration termination
15 Jul 16
EFFECT
Notice of effectiveness
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Jul 16
Latest ownership filings
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|